Zimmer Biomet (ZBH) is an average quality business scoring 57/100. While the company generates positive returns, it lacks the exceptional attributes that characterize durable competitive advantages. Investors should demand a meaningful discount to fair value before investing.
Zimmer Biomet shows a solid competitive position with solid gross margins of 70.8%. However, returns on capital that fall short of elite levels suggests the moat, while present, may face challenges. The business earns above-average returns but lacks the exceptional durability of the strongest moats.
Zimmer Biomet has limited pricing power. The company operates with margins that are average for its industry, and revenue growth has come with some margin pressure. This suggests the business competes partially on price rather than on differentiated value.
Zimmer Biomet has moderate predictability. Financial results have shown some volatility, with periods of uneven revenue or cash flow performance. While the business generates returns, forecasting its near-term trajectory requires more caution due to this variability.
Zimmer Biomet maintains a solid financial position. Debt levels are manageable, and the company generates sufficient cash to service its obligations. While not a fortress balance sheet, the financial position poses no immediate concerns and provides reasonable flexibility.
Zimmer Biomet shows solid capital allocation. Returns on capital exceed the cost of capital, and management balances reinvestment with shareholder returns reasonably well. There is room for improvement, but overall capital deployment creates value.
Zimmer Biomet's management shows mixed results. Operational efficiency could be improved, and capital deployment decisions have been inconsistent. The team needs to demonstrate clearer focus on shareholder value creation.

Predicted probability of operating margin improvement over the next 12 months
Is Zimmer Biomet a good investment at $91?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.